Showing 4131-4140 of 5000 results for "".
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- 2022 Monkeypox Outbreak: Here’s What Dermatologists Need to Knowhttps://practicaldermatology.com/news/2022-monkeypox-outbreak-heres-what-dermatologists-need-to-know/2461210/As case counts of monkeypox cases increase in Europe and other parts of the globe including the US, dermatologists may have an important role to play in terms of making differential diagnoses. George Han, MD a dermatologist at Lenox Hill Hospital in New York City, spoke to Practical
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- Three Beliefs Affect Older Adults Sunscreen Usehttps://practicaldermatology.com/news/three-beliefs-affect-older-adults-sunscreen-use/2461202/Reminders from a romantic partner might be an effective way to encourage sunscreen use by people age 50 or older, suggests a study in the May/June issue of The Journal of the Dermatology Nurses' Association. People older than 50 are also more likely to use su
- Cynosure Scores $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://practicaldermatology.com/news/cynosure-scores-60-million-follow-on-investment-from-clayton-dubilier-rice/2461199/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that
- Barbie Launches Ken Doll with Vitiligohttps://practicaldermatology.com/news/barbie-launches-ken-doll-with-vitiligo/2461197/Mattel, the parent company for Barbie, will include a Ken doll with vitiligo as part of their 2022 Fashionistas line. The Barbie Fashionistas line includes Barbie dolls with more variety of skin tones, eye colors, hair colors and textures, body types, disabilities, and fashions.
- Eucerin Launches Skin-focused Sun Care Line in the UShttps://practicaldermatology.com/news/eucerin-launches-skin-focused-sun-care-line-in-the-us/2461196/Eucerin is expanding into the US sun protection market with its new Eucerin Sun line. Developed with dermatologists and consisting of seven products across face and body, Eucerin Sun is formulated with a five antioxidants to go beyond sun protection and help promote healthy-looking
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u
- Indoor Tanning Ban Could Slash Melanoma Deathshttps://practicaldermatology.com/news/indoor-tanning-ban-could-slash-melanoma-deaths/2461190/An indoor tanning ban in England would reduce melanoma deaths, according to a study by University of Manchester researchers. By tracking the projected impact on the 618,000 18-year-olds living in England in 2019, the research team showed that a ban on indoor tanning would resu